HepaTx Corporation
PrivateLast Round
Grant
May 20, 2025
Est. Valuation
$2.14M
Total Funding Raised
$475,032
Company Overview
HepaTx Corporation is a biotechnology company that specializes in regenerative medicine and the development of stem cell-based therapies for patients with late-stage liver disease.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
HepaTx Corporation Comparables
Compare HepaTx Corporation with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Senno Therapeutics Inc. | 84% | |
| LyGenesis | 83% | |
| GoLiver Therapeutics | 82% |
HepaTx Corporation Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | May 20, 2025 | ||||
| Seed | May 1, 2021 | ||||
| Grant | Sep 1, 2019 | ||||
| Accelerator | Aug 21, 2018 |
HepaTx Corporation Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| StartX | Accelerator |
| NIH RADx | Grant |
| Bioverge | Seed |
| National Institute of Diabetes and Digestive and Kidney Diseases | Grant |
| National Institute of Diabetes and Digestive and Kidney Diseases | Grant |
| Y Combinator | Accelerator |
| Sand Hill Angels | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 20, 2025
$176K grant from National Institute of Diabetes and Digestive and Kidney Diseases.
- May 1, 2021
Seed round raised with Bioverge and Sand Hill Angels.
HepaTx Corporation Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about HepaTx Corporation's valuation, stock price, and market status.
Is HepaTx Corporation a public or private company?
HepaTx Corporation is a private company.
What is the current stock price of HepaTx Corporation?
HepaTx Corporation is a private company with no public stock price. No recent secondary market data is available.
How much is HepaTx Corporation worth (valuation)?
HepaTx Corporation's valuation is estimated at $2.1M based on funding round data.
Can I buy HepaTx Corporation stock?
HepaTx Corporation shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was HepaTx Corporation's last funding round?
HepaTx Corporation's most recent funding round was Grant on August 21, 2018.
Who are the main investors in HepaTx Corporation?
Key investors in HepaTx Corporation include NIH RADx, National Institute of Diabetes and Digestive and Kidney Diseases, Y Combinator.
Will HepaTx Corporation IPO soon?
No public IPO plans have been announced for HepaTx Corporation.
How can I track HepaTx Corporation secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor HepaTx Corporation's secondary market activity and sign up for updates.